about
sameAs
Second consensus statement on the diagnosis of multiple system atrophyWhat clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?The motor disorder of multiple system atrophy.Genetic variation of CHRNA4 does not modulate attention in Parkinson's diseaseClinicopathological study of 35 cases of multiple system atrophy.Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET dataMultiple system atrophy: current and future approaches to managementThe symptomatic treatment of multiple system atrophy.Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.The pathophysiology of parkinsonism in multiple system atrophy.Clinical manifestations of Parkinson's disease and parkinsonism.Dystonia in multiple system atrophy.Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imagingCombination therapies: The next logical Step for the treatment of synucleinopathies?Cognitive impairment and dementia in patients with Parkinson disease.Multiple system atrophy of the cerebellar type: clinical state of the art.Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.Near-Infrared Spectroscopy in Gait Disorders: Is It Time to Begin?Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy.Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.Freezing of gait in postmortem-confirmed atypical parkinsonism.Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.Diagnosis of multiple system atrophy.Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease.Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch.Intrathecal baclofen therapy slows progressive disability in multiple system atrophy.Patient characteristics, MRI examination, and dopaminergic drug response in clinical possible Parkinson's disease.Utility of the fluid-attenuated inversion recovery sequence in detecting a hyperintense putaminal rim in multiple system atrophy-parkinsonism: a preliminary study.Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.Blinking in patients with clinically probable multiple system atrophy
P2860
Q24650965-03AEEF22-5C91-4E3F-BD0E-EABBD3D0E4C2Q33180015-5581C684-6A82-4F9A-8B66-A427F0977E6BQ33592243-1AF49DD0-ABDE-4621-94E1-9D8E63113D3DQ33685603-10A07A39-4003-4BB3-B51D-56DA55F0050DQ33733668-8174BA2C-C4CB-4065-BEDD-ACAE38A60978Q34060625-854E703D-0C88-4368-94FD-8CD7B94342E8Q34409502-07DAA486-EFF1-4105-BD2F-AFBEBFDB84E2Q34621628-7CC84D5F-7F80-4E3C-A6BC-4BF143A8EB12Q34767058-8D9745A5-3D13-4878-8196-AEC583A43EBAQ35055565-C64BF742-2121-400F-8539-76A75C920F07Q35105734-2F8FB3E4-988C-4023-B39F-43F725918AEBQ35466200-9D420127-A436-4A80-9230-C002D268C5F5Q35470123-5D2DFAD6-3A97-40F7-A648-A251BAB86F89Q36563062-C3C66E0E-B55F-4EB3-9EC6-58F6554B31C7Q37597279-6EBA625C-D2B4-47E8-9454-7E2244B4DD25Q38194974-18F62B67-E029-4703-9A3D-DE0B61DEFEC4Q38237228-DF2C40C4-90E4-4A2F-8D5B-46697D571F1AQ38961955-A972061E-4907-4F5F-9BC1-C62BCDCEECA4Q39784721-4F112E4A-07BF-41BC-9FF4-C4998147AAF7Q39830590-5974BD24-8A5A-475F-AE80-7747EEC2FE65Q40202363-0AF35F98-027E-41E0-B3CE-94808CDBBF0EQ40629446-9554B4AA-94A0-4BA5-8E66-617E092F9E95Q43570440-3C136D7F-4EAC-440A-9EC5-F5D941348C7FQ47665262-42B118A7-3ACA-411F-9C7A-277B840BE26BQ48198969-D4A53782-CB5F-4639-AA6E-F2EC248A529DQ48437243-79975EFD-C7DB-4429-A4E6-3F373141C9E8Q48571502-05EA319B-AFBC-4418-8055-AFEA179AD3DAQ48895388-FF4DFF5A-1CA4-48F8-A769-8CD2BBADABFCQ49046996-C3AA9CB3-F4AD-43C5-8271-E441D8B4DF18Q51294100-2DE7A11B-2F16-4587-80B7-A1C3AB2554C8Q51953568-1A298F44-F7A0-4CED-8932-A2F679B675ADQ56975288-29437F8C-7F2A-4699-B0B1-0D6F3372B9D6
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The dopaminergic response in multiple system atrophy
@nl
The dopaminergic response in multiple system atrophy.
@ast
The dopaminergic response in multiple system atrophy.
@en
type
label
The dopaminergic response in multiple system atrophy
@nl
The dopaminergic response in multiple system atrophy.
@ast
The dopaminergic response in multiple system atrophy.
@en
prefLabel
The dopaminergic response in multiple system atrophy
@nl
The dopaminergic response in multiple system atrophy.
@ast
The dopaminergic response in multiple system atrophy.
@en
P2093
P2860
P356
P1476
The dopaminergic response in multiple system atrophy.
@en
P2093
Kleedorfer B
P2860
P304
P356
10.1136/JNNP.55.11.1009
P407
P577
1992-11-01T00:00:00Z